Trump's focus on local drugs not immediate concern: Indian pharma industry

US is one of the major export destinations for drugmakers in India, accounting for roughly 33 per cent of the country's drug exports

As the US tries to reduce dependence on drugs from other countries, especially essential generic drugs, demand issues can arise for Indian exporters. The local industry in India, however, feels that creating indigenous capacity to manufacture drugs would take time, and also prove to be expensive for the US.

President Donald Trump's administration awarded a contract worth nearly $812 million over ten years to a newly incorporated US company called Phlow Corporation to manufacture drugs and even active pharmaceutical ingredients (APIs) in the US to fight Covid-19.

US is one of the major export destinations for drugmakers in India, accounting